ImmunoPrecise Antibodies Ltd. (HYFT) — Capital Reinvestment Ratio

Latest as of October 2020: 1.62x

ImmunoPrecise Antibodies Ltd. (HYFT) has a Capital Reinvestment Ratio of 1.62x as of October 2020, meaning it reinvests 2% of its operating cash flow ($440.23K) in capital expenditures ($715.21K). Check HYFT tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

1.62x
Capex / Operating Cash Flow

Operating Cash Flow

$440.23K
USD

Capital Expenditures

$715.21K
USD

Data as of

Oct 2020
Most recent filing

ImmunoPrecise Antibodies Ltd. Capital Reinvestment Ratio (2016–2016)

This chart tracks ImmunoPrecise Antibodies Ltd.'s Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see cash flow conversion of ImmunoPrecise Antibodies Ltd..

Annual Capital Reinvestment Ratio for ImmunoPrecise Antibodies Ltd. (2016–2016)

Year-by-year Capital Reinvestment Ratio for ImmunoPrecise Antibodies Ltd. from 2016 to 2016. See how much free cash does ImmunoPrecise Antibodies Ltd. generate to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2016 0.06x $284.09K $17.48K —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow